Dr. Flemming Forsberg, PhD
Claim this profileThomas Jefferson University, Dept of Radiology
Studies Liver Disease
Studies Hypertension
3 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Flemming Forsberg, PhD is currently running
Noninvasive SHAPE
for Portal Hypertension
This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University of Pennsylvania (HUP) and University of Bern (UB). Enrollment will be allocated into one of 4 different cohorts depending on the inclusion criteria for each cohort. Cohort 1: Patients scheduled for hepatic vein pressure gradient (HVPG) measurements will subsequently undergo two consecutive SHAPE (subharmonic aided pressure estimation) procedures using different ultrasound contrast agents (Definity \[Lantheus Medical Imaging, N Bilerica, MA, USA\] and Sonazoid \[GE Healthcare, Oslo, Norway\] in randomized order) to estimate portal pressures with a Logiq E10 scanner (GE Healthcare, Waukesha, WI, USA) and determine the reproducibility of the SHAPE algorithm. Cohort 2: Patients identified as having clinically significant portal hypertension (CSPH) will be monitored by SHAPE with Sonazoid for the duration of this project (18-24 months on average). These subjects will have follow-up ultrasound scans every 6 ± 2 months to check for hepatocellular carcinoma (HCC) (using the Barcelona-Liver Cancer staging system) as well as ascites and at those times a repeat SHAPE examination will be performed. Liver stiffness values will be measured with elastography as well. This cohort will examine if serial SHAPE can accurately predict development of ascites and other liver related events in patients with compensated cirrhosis undergoing routine HCC surveillance in a multi-center setting. Cohort 3: Subjects newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE and results compared to elastography measurements of liver stiffness with standard assessments (e.g., serum liver function tests and measurement of spleen size as well as platelet count). This cohort will establish if SHAPE can be used to monitor treatment response in patients identified with portal hypertension. Cohort 4: Patients with compensated advanced chronic liver disease scheduled for an endoscopy examination for screening of varices relative to the Baveno VI and the expanded-Baveno VI criteria as well as the AST to Platelet Ratio Index will undergo a SHAPE examination. This cohort will compare the predictive ability of SHAPE for allocating patients with compensated advanced chronic liver disease to screening of varices compared to the current standard of care.
Recruiting4 awards Phase 39 criteria
Sonoporation + Chemotherapy
for Pancreatic Cancer
This phase I/II trial studies the effect of sonoporation in addition to standard of care chemotherapy in treating patients with pancreatic cancer. Sonoporation is a novel method that uses ultrasound and microbubbles to increase therapeutic effect by increasing uptake or enhance sensitization. Sonoporation together with chemotherapy may work better in treating patients with pancreatic cancer compared to chemotherapy alone.
Recruiting1 award Phase 1 & 214 criteria
More about Flemming Forsberg, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Flemming Forsberg, PhD has experience with
- SHAPE Measurement (Definity Ultrasound Contrast Agent)
- SHAPE Measurement (Sonazoid Ultrasound Contrast Agent)
- Gemcitabine Hydrochloride
- Irinotecan Hydrochloride
- Nab-paclitaxel
- Sonoporation
Breakdown of trials Flemming Forsberg, PhD has run
Liver Disease
Hypertension
Portal Hypertension
Liver cirrhosis
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Flemming Forsberg, PhD specialize in?
Flemming Forsberg, PhD focuses on Liver Disease and Hypertension. In particular, much of their work with Liver Disease has involved treating patients, or patients who are undergoing treatment.
Is Flemming Forsberg, PhD currently recruiting for clinical trials?
Yes, Flemming Forsberg, PhD is currently recruiting for 2 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Flemming Forsberg, PhD has studied deeply?
Yes, Flemming Forsberg, PhD has studied treatments such as SHAPE measurement (Definity ultrasound contrast agent), SHAPE measurement (Sonazoid ultrasound contrast agent), Gemcitabine Hydrochloride.
What is the best way to schedule an appointment with Flemming Forsberg, PhD?
Apply for one of the trials that Flemming Forsberg, PhD is conducting.
What is the office address of Flemming Forsberg, PhD?
The office of Flemming Forsberg, PhD is located at: Thomas Jefferson University, Dept of Radiology, Philadelphia, Pennsylvania 19107 United States. This is the address for their practice at the Thomas Jefferson University, Dept of Radiology.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.